L

LegoChem Biosciences Inc
KOSDAQ:141080

Watchlist Manager
LegoChem Biosciences Inc
KOSDAQ:141080
Watchlist
Price: 107 600 KRW 4.16% Market Closed
Market Cap: 3.9T KRW
Have any thoughts about
LegoChem Biosciences Inc?
Write Note

LegoChem Biosciences Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LegoChem Biosciences Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
L
LegoChem Biosciences Inc
KOSDAQ:141080
Other Equity
â‚©8.4B
CAGR 3-Years
59%
CAGR 5-Years
78%
CAGR 10-Years
49%
Samsung Biologics Co Ltd
KRX:207940
Other Equity
-â‚©874.5B
CAGR 3-Years
-248%
CAGR 5-Years
-109%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Other Equity
â‚©4.3B
CAGR 3-Years
103%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Other Equity
â‚©14.5B
CAGR 3-Years
45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Other Equity
â‚©1.1B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Other Equity
â‚©10.4B
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LegoChem Biosciences Inc
Glance View

Market Cap
3.9T KRW
Industry
Life Sciences Tools & Services

LegoChem Biosciences Inc., rooted in South Korea, is navigating the complex world of pharmaceutical innovation with a focus sharp enough to captivate both scientists and investors. Founded in 2006, the company has honed its expertise particularly in the field of antibody-drug conjugates (ADCs). This novel approach merges the targeting capabilities of antibodies with the cancer-killing prowess of chemotherapy drugs, aiming to deliver high precision in cancer treatment while minimizing side effects. LegoChem conducts meticulous research and development, advancing its proprietary ConjuAll™ technology platform, which enhances the stability and efficacy of ADCs. This dedication to scientific innovation underscores the company's strategy of robust collaboration and partnerships with global pharmaceutical giants, enabling it to leverage complementary expertise and expedite the commercialization of its cutting-edge therapies. LegoChem Biosciences generates revenue primarily through a strategic business model that revolves around licensing agreements and research collaborations with major pharmaceutical players. The company enters into partnerships where it licenses out its advanced drug discovery platforms, receiving upfront payments, milestones based on developmental progress, and royalties upon successful commercialization of its licensed products. These collaborative strategies not only finance ongoing research but also diversify revenue streams and mitigate the inherent financial risks associated with drug development. By focusing on areas with high unmet medical needs, LegoChem not only positions itself advantageously in the competitive biotech landscape but also aligns with a mission to transform lives through innovation. With a clear-eyed vision and strategic partnerships, LegoChem Biosciences Inc. continues its quest to make significant strides in the realm of targeted cancer therapies.

Intrinsic Value
25 726.99 KRW
Overvaluation 76%
Intrinsic Value
Price
L

See Also

What is LegoChem Biosciences Inc's Other Equity?
Other Equity
8.4B KRW

Based on the financial report for Sep 30, 2024, LegoChem Biosciences Inc's Other Equity amounts to 8.4B KRW.

What is LegoChem Biosciences Inc's Other Equity growth rate?
Other Equity CAGR 10Y
49%

Over the last year, the Other Equity growth was 13%. The average annual Other Equity growth rates for LegoChem Biosciences Inc have been 59% over the past three years , 78% over the past five years , and 49% over the past ten years .

Back to Top